01589nam a2200253   45000010005000000100015000051000041000201010008000612000163000692100083002322150023003152250040003383000132003783300585005106060022010956060034011176060033011516060022011846060013012066060012012196060024012317100069012558520011013247554  a9291681237  a20020716d2002       y0pory50      ba  aeng  aReport on the risk assessment of ketamine in the framework of the joint action on new synthetic drugsfEuropean Monitoring Centre for Drugs and Drug Addiction  aLuxembourgcOffice for Official Publications of the European Communitiesd2002  a116 p.cil.d21 cm  aImplemention of the joint actionv3  aInformação sobre European Monitoring Centre for Drugs and Drug Addiction pode ser encontrada no site: https://www.emcdda.org  aReport on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs. Europol-EMCDDA progress report on ketamine in accordance with Article 3 of the joint action of 16 june 1997 concerning the information exchange, risk assessment and the control of new synthetic drugs. Use of ketamine in human medicine in the EU Member States. Use of ketamine in veterinary medicine in the EU Member States. Review of the pharmacotoxicological data on ketamine. Sociological and criminological (Europol) evidence. Public health risks - epidemiological evidence.  aDROGAS ILÍCITAS  aSUBSTÂNCIAS PSICOTRÓPICAS  aCOOPERAÇÃO INTERNACIONAL  aSAÚDE PÚBLICA  aMEDICINA  aEUROPOL  aCONSELHO DA  EUROPA  aEUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION - EMCDDA  jDRO320